Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms ...

Levels of C4d and C4d/C4 associate with clinical and histopathological treatment response in proliferative lupus nephritis. Complement activation markers, particularly C4d and the C4d/C4 ratio, are ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with ...

Some patients with SLE and low-grade proteinuria may have early active lupus nephritis. Current systemic lupus erythematosus (SLE) guidelines recommend performing a kidney biopsy in patients with a ...

An Alexion Pharmaceuticals Inc. patent describes new complement C1s subcomponent (C1S) inhibitors potentially useful for the treatment of immune thrombocytopenia purpura, lupus nephritis, amyotrophic ...

Biomarkers can serve as early warning signs for individual health and can help indicate certain diseases. In a new study, researchers examined levels of microvascular C5b-9 (a protein found on the ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Persistent hematuria was predictive of adverse outcomes among patients with LN, regardless of achieving clinical remission.